文献速递传染病防控与疫情报告免疫规划

候选C端结构域OspA疫苗预防莱姆病的保护特性

Protective properties of a candidate C-terminal domain OspA vaccine for prevention of Lyme disease.
PubMed 文献 · Vaccine · 2026-01-29

莱姆病是公共卫生问题,OspA抗体可阻断蜱传伯氏疏螺旋体感染。候选疫苗VLA15包含北美和欧洲流行的六种OspA血清型C端结构域。非人灵长类免疫VLA15后,可抵御携带伯氏疏螺旋体(OspA ST1)的肩突硬蜱攻击。

要点

  • VLA15免疫的非人灵长类可抵抗携带伯氏疏螺旋体(OspA ST1)的蜱攻击。
  • VLA15免疫后蜱内残留螺旋体定植水平低于全长OspA ST1免疫。
  • 靶向OspA C端半区的单克隆抗体在体外杀菌和蜱内清除螺旋体更有效。

核心结论

  • VLA15免疫可保护非人灵长类免受携带伯氏疏螺旋体(OspA ST1)的肩突硬蜱攻击。

研究设计与样本

  • 非人灵长类免疫VLA15后,以携带伯氏疏螺旋体sensu stricto(OspA ST1)的肩突硬蜱进行攻击试验。

主要发现

  • VLA15免疫的非人灵长类受到保护,未发生伯氏疏螺旋体感染。
  • 与全长OspA ST1免疫相比,VLA15免疫后蜱内残留伯氏疏螺旋体定植水平降低,且此时OspA结合IgG水平相似。
  • 由全长OspA免疫灵长类产生的靶向OspA C端半区的单克隆抗体,在体外补体介导杀菌和蜱内螺旋体清除方面优于靶向其他区域的抗体。

临床怎么用

  • VLA15作为候选疫苗,其C端结构域设计在非人灵长类中显示保护效果,支持进一步临床开发。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Lyme disease is a growing public health concern that is geographically focused in regions where ticks that carry the causative bacteria, Borrelia burgdorferi sensu lato (s.l.), are endemic. Outer surface protein A (OspA) is expressed by B. burgdorferi s.l. spirochetes during the tick phase and OspA antibodies introduced during tick feeding can block transmission and prevent B. burgdorferi infection. Candidate Lyme disease vaccine VLA15 is comprised of the C-terminal domains of the six B. burgdorferi s.l. OspA serotypes (ST) prevalent in North America and Europe. We report herein that non-human primates immunized with VLA15 were protected against challenge with Ixodes scapularis ticks bearing B. burgdorferi sensu stricto (s.s.) (OspA ST1). Levels of residual B. burgdorferi s.s. tick colonization were reduced in ticks that fed on VLA15-immunized primates compared to those immunized with full length-OspA ST1 (FL-OspA) at a point when OspA-binding IgG levels were similar. Furthermore, monoclonal antibodies targeting the C-terminal half of OspA, elicited by FL-OspA immunization in primates, were more effective at complement-mediated bactericidal killing in vitro and clearance of spirochetes in ticks versus those directed against other parts of the protein.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Embers ME, Hasenkampf NR, Tardo AC, et al. Protective properties of a candidate C-terminal domain OspA vaccine for prevention of Lyme disease. Vaccine. 2026. PMID: 41616647. doi:10.1016/j.vaccine.2026.128231

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。